GRI Bio, Inc. Files 8-K

Ticker: GRI · Form: 8-K · Filed: May 5, 2025 · CIK: 1824293

Sentiment: neutral

Topics: corporate-filing, pharmaceuticals, financial-reporting

TL;DR

GRI Bio filed an 8-K on 5/5/25, check it for company updates.

AI Summary

GRI Bio, Inc. filed an 8-K on May 5, 2025, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc. and GRI BIO, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector.

Why It Matters

This filing provides an update on GRI Bio, Inc.'s corporate activities and financial reporting, which is important for investors to track the company's status.

Risk Assessment

Risk Level: low — This is a routine filing reporting corporate events and financial statements, not indicating any immediate material changes or risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of May 5, 2025.

What are the former names of GRI Bio, Inc.?

GRI Bio, Inc. was formerly known as GRI BIO, Inc. (effective April 24, 2023) and prior to that, Vallon Pharmaceuticals, Inc. (effective September 10, 2020).

Where are GRI Bio, Inc.'s principal executive offices located?

GRI Bio, Inc.'s principal executive offices are located at 2223 Avenida de la Playa, #208 La Jolla, CA 92037.

What is the Standard Industrial Classification (SIC) code for GRI Bio, Inc.?

The SIC code for GRI Bio, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

On what date was this 8-K report filed?

This 8-K report was filed on May 5, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 5, 2025 regarding GRI Bio, Inc. (GRI).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing